the low incidence of severe side effects makes sulfasalazine a consideration for oral therapy in patients whose disease severity does not justify use of methotrexate , etretinate , or psoralen plus uv-a , but whose disease severity is too widespread for safe and practical use of topical corticosteroids .
C0025677
methotrexate
C0015137
etretinate